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Abstract
Background: Consumption of plant sterol (PS) esters lower low-density lipoprotein (LDL)-cholesterol levels by
suppressing intestinal absorption of cholesterol. Commercially available PS are mainly esterified to omega-6 fatty acid
(FA), such as sunflower oil (SO) FA. Emerging trends include using other sources such as olive oil (OO) or omega-3 FA
from fish oil (FO), known to exert potent hypotriglyceridemic effects. Our objective was to compare the actions of
different FA esterified to PS on blood lipids, carotenoid bioavailability as well as inflammatory and coagulation markers.
Methods: Twenty-one moderately overweight, hypercholesterolemic subjects consumed experimental isoenergetic
diets enriched with OO (70% of fat), each lasting 28-day and separated by 4-week washout periods, using a randomized
crossover design. Diets were supplemented with three PS esters preparations, PS-FO, PS-SO, or PS-OO. All PS
treatments contained an equivalent of 1.7 PS g/d, and the PS-FO provided a total of 5.4 g/d FO FA (eicosapentaenoic and
docosahexaenoic acids).
Results: There were no differences between PS-containing diet effects on total cholesterol, LDL-cholesterol, or high-
density lipoprotein (HDL)-cholesterol levels. However, PS-FO consumption resulted in markedly lower (P < 0.0001)
fasting and postprandial triglyceride concentrations compared with PS-SO and PS-OO. These treatments affected plasma
β-carotene (P = 0.0169) and retinol (P = 0.0244), but not tocopherol (P = 0.2108) concentrations. Consumption of PS-
FO resulted in higher β-carotene (P = 0.0139) and retinol (P = 0.0425) levels than PS-SO and PS-OO, respectively. Plasma
TNF-α, IL-6, C-reactive protein, prostate specific antigen, and fibrinogen concentrations were unaffected by the PS-
interventions. In contrast, plasminogen activator inhibitor 1 (PAI-1) concentrations were lower (P = 0.0282) in the PS-
FO-fed than the PS-SO, but not the PS-OO (P = 0.7487) groups.
Conclusion: Our findings suggest that, in hypercholesterolemic subjects consuming an OO-based diet, PS-FO results in
lowered blood triglyceride and PAI-1 concentrations, and higher fat-soluble vitamin levels in comparison to the vegetable
oil FA esters of PS (PS-SO and PS-OO). Thus, PS-FO may offer hyperlipidemic subjects a more comprehensive lipid
lowering approach while reducing the potential risk of decreased plasma carotenoid concentrations.
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Background
Complications of atherosclerosis are considered the lead-
ing cause of death in Western societies and have an
extremely high incidence in type 2 diabetes mellitus
patients [1]. It is well established that elevated serum low-
density lipoprotein (LDL)-cholesterol concentrations are
a major risk factor for atherosclerotic disease [2]. Recent
reports favored LDL-cholesterol lowering not only in indi-
viduals with coronary artery disease or severely elevated
blood cholesterol concentrations, but also in healthy per-
sons with only mild-to-moderate hypercholesterolemia
[3-5]. Plant sterols (PS) or phytosterols such as β-sito-
sterol, campesterol, and stigmasterol occur naturally and
are structurally similar to cholesterol, but an additional
hydrocarbon chain at carbon 24 and a double bond on
the side chain [6]. PS intake in Western diets is estimated
to be equivalent to that of dietary cholesterol, i.e. below
500 mg/d. Recently, consumption of 2 g/d of PS for LDL-
cholesterol lowering was recommended by the National
Cholesterol Education Program [3] as part of the standard
therapy to reduce the risk for coronary heart disease
(CHD). The exact mechanism by which dietary PS con-
sumption affect blood cholesterol level is not fully under-
stood; however, it has been suggested that their greater
hydrophobicity result in higher affinity for micelles than
cholesterol [7]. Therefore, digested PS may displace intes-
tinal cholesterol from the micelles, thus reducing intesti-
nal cholesterol absorption and reabsorption [8]. Such a
reduction results in compensatory increases in endog-
enous cholesterol synthesis [8] and higher LDL-receptor
expression [9]. The net overall effect is that circulating
LDL-cholesterol concentrations are lowered. However, PS
intervention could also lead to a small reduction in
plasma concentrations of lipophilic carotenoids including
β-carotene as well as vitamin A and possibly vitamin E
[10-12].
Accumulated evidence has associated dietary PS impact
on circulating LDL-cholesterol with their solubilization in
the provided preparations [see review in [13]]. In several
reports, emulsification of PS with lecithin, sucrose esters,
DAG or in different food matrices was suggested as
increasing their bioavailability into the intestinal micelles
[14]. Nonetheless, PS esterification to long-chain fatty
acid (FA) is the most common solubilization method in
food preparations [10,15] and dietary supplements
[16,17]. Esterifying PS to vegetable oils FA from sun-
flower, soybean, or rapeseed increases their incorporation
into fat-containing products by 10-fold while maintaining
their cholesterol absorption inhibiting functions [10,15].
In contrast to the current practice in the food industry,
recent studies used animal fat, such as beef tallow [18] or
fish oil (FO) [19-22], as the FA source for PS esterification.
Consumption of the latter was reported to favorably affect
other key and independent risk factors associated with
CHD, such as elevated plasma triglyceride levels [23].
Indeed, PS esters of fish-oil FA provided to animal models
favorably altered both non-high density lipoprotein
(HDL)-cholesterol and triglyceride serum concentrations
[20-22].
Most of the randomized clinical trials testing food matri-
ces containing PS in normo- to hyper-cholesterolemic
individuals [10,15] have focus on their cholesterol lower-
ing properties. Additionally, several studies have further
examined the impact of these PS preparations on lipid
peroxidation [24-26], endothelial markers [26,27],
inflammation markers [16,26,28-30], as well as their anti-
cancer effects [see review in [31]]. However, systematic
investigation of the impact of different FA classes esteri-
fied to PS on plasma cholesterol concentrations or other
risk factors has not yet been carried out in human. Our
objective was to compare the effects of PS esterified to
sunflower oil (omega-6; PS-SO), olive oil (omega-9; PS-
OO), or FO (omega-3; PS-FO) FA on lipids profile, fat-sol-
uble vitamins bioavailability, as well as on inflammation-
and coagulation-related marker levels in mildly over-
weight, hyperlipidemic subjects.
Results
Subjects
The study was initiated with 11 males and 13 females who
met the trial criteria. There were three dropouts due to per-
sonal reasons (n = 2) and FO-associated gastrointestinal
discomfort (n = 1). Baseline characteristics of the 21 sub-
jects who completed the study are shown in Table 1. Mean
baseline body weight, as well as the indicated plasma lip-
ids, did not differ between the PS containing treatments
(data not shown).
Plasma lipid levels
Plasma lipid concentrations at the end of the different PS
ester treatments are shown in Table 2. No differences were
detected in total cholesterol or LDL-cholesterol concentra-
tions following supplementation of OO-based diet with
PS esterified to SO, OO, or FO FA (Table 2). Nonetheless,
consumption of these dietary matrices, i.e. PS-SO, PS-OO,
or PS-FO significantly lowered total cholesterol (an effect
size of -0.61, -0.66, or -0.72, respectively), and LDL-cho-
Table 1: Baseline characteristics of the study subjects (n = 11 
males, 10 females)
Age (y) 54.19 ± 1.621
Weight (kg) 73.69 ± 2.72
BMI (kg/m2) 25.93 ± 0.62
Total cholesterol (mmol/L) 6.09 ± 0.18
LDL-cholesterol (mmol/L) 3.91 ± 0.12
HDL-cholesterol (mmol/L) 1.28 ± 0.07
Triacylglycerol (mmol/L) 1.77 ± 0.25
1 Values are means ± SEs.Lipids in Health and Disease 2007, 6:28 http://www.lipidworld.com/content/6/1/28
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lesterol (an effect size of -0.58, -0.55, or -0.45, respec-
tively) concentrations, when compared to the indicated
phases baseline values (data not shown). A tendency
towards a reduction (Table 2) in HDL-cholesterol concen-
trations was also observed, albeit the overall impact was
fairly small. Effects of these PS containing supplements on
fasting and postprandial triglycerides plasma concentra-
tions differed significantly (Table 2). PS-FO resulted in
lower fasting triglyceride concentrations than those
observed with PS-SO (P  = 0.0001) and PS-OO (P  <
0.0001). Similar differences between these interventions
were shown in postprandial triglyceride concentrations (P
< 0.0001). Consumption of PS esterified to vegetable oil
FA, i.e. PS-SO and PS-OO, had comparable (P = 0.7404)
and relatively small (an effect size of -0.22, and -0.25,
respectively) impacts on fasting and postprandial (P  =
0.8380) triglyceride concentrations.
Fat-soluble vitamins
Consumption of the various PS containing preparations
had different effects on plasma concentrations of retinol
and β-carotene, but not α-tocopherol (Table 3). Specifi-
cally, the PS-FO-fed group exhibited higher retinol con-
centrations as compared with the PS-OO (P = 0.0425) but
not the PS-SO (P = 0.0638) groups. In addition, plasma β-
carotene concentrations following PS-FO feeding were
elevated in comparison with PS-SO (P = 0.0139), but not
PS-OO (P = 0.2376). No differences between PS-SO and
PS-OO groups were detected in retinol and β-carotene
concentrations (P = 0.9974, and 0.5302), respectively.
Circulating inflammatory markers and blood coagulation 
markers
Effects of different PS esters containing treatments on
plasma inflammatory and coagulation markers are shown
in Table 4. Plasma tumor necrosis factor – α (TNF-α),
interleukin-6 (IL-6), C-reactive protein (CRP), prostate
specific antigen (PSA), and fibrinogen concentrations
were unaffected by the consumption of the different die-
tary treatments (Table 4). However, the consumption of
PS-FO resulted in lowered plasminogen activator inhibi-
tor 1 (PAI-1) concentrations compared with PS-SO (P =
0.0282), but not PS-OO (P = 0.7487). There were no dif-
ferences (P = 0.2080) between the effects of PS esterified
to SO and OO FA on PAI-1 concentrations.
Discussion
The present findings show that in healthy mildly over-
weight hypercholesterolemic subjects consumption of PS-
FO differs from PS-OO and PS-SO in its impact on plasma
triglyceride and fat-soluble vitamin levels. In addition, the
PS-FO treatment resulted in lowered PAI-1 concentrations
as compared to the interventions with PS-SO, but not PS-
OO. Taken together, these observations suggest that the
PS carriers may play, at least in part, a role in the exerted
effects of various PS-preparations.
To date, PS esters provided as food matrices, mostly as
spreads or in soft gel capsules, have been shown to affect
LDL-cholesterol concentrations in both normo- and
hypercholesterolemic individuals [10,15-17,32] How-
ever, the influence of the FA esterified to PS on the overall
PS ester effect remains poorly studied. We have compared
the cholesterol-lowering abilities of PS esterified to differ-
ent FA. No differences between these treatments on blood
cholesterol were detected. It has been previously shown
that consumption of commercial PS ester spreads, such as
PS-SO spread, has an impact on LDL-cholesterol concen-
trations comparable to that of PS-FO [19,28] or PS-OO
[25]. Preliminary observations have linked the type of
food matrix enriched with PS esters to different choles-
terol-lowering effects [33]. In contrast, PS esterified to
stearic acid were recently shown to be more effective than
PS-SO in lowering both blood and liver cholesterol con-
centrations in hamsters [18]. The exact mechanism by
which these supplements elicit differential effects on
Table 2: Endpoint fasting and postprandial plasma lipid concentrations (n = 21)
PS-SO2 PS-OO PS-FO P value3
Cholesterol
Total (mmol/L) 5.61 ± 0.211 5.49 ± 0.25 5.48 ± 0.23 0.5793
LDL (mmol/L) 3.59 ± 0.16 3.48 ± 0.19 3.73 ± 0.17 0.2704
HDL (mmol/L) 1.29 ± 0.07 1.23 ± 0.07 1.30 ± 0.07 0.0767†
Triacylglycerols
Fasting (mmol/L) 1.62 ± 0.19a 1.75 ± 0.25a 0.99 ± 0.12b < 0.0001
Postprandial (mmol/L) 2.56 ± 0.23a 2.70 ± 0.23a 1.53 ± 0.15b < 0.0001
1 Values are means ± SEs.
2 PS-SO: plant sterols esterified with sunflower oil fatty acids; PS-OO: plant sterols esterified with olive oil fatty acids; PS-FO: plant sterols esterified 
with fish oil fatty acids
3 P values obtained by repeated-measures ANOVA with † baseline concentrations included in the model as covariates. Values of plasma triglyceride 
concentrations were normalized using a log transformation.
a, b Values not sharing a common superscript letter are significantly different at P < 0.05.Lipids in Health and Disease 2007, 6:28 http://www.lipidworld.com/content/6/1/28
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blood cholesterol concentrations remained unclear; nev-
ertheless, the authors speculated that these findings may
be associated with the combined effects of free PS and
stearic acid. These observations may suggest that the cho-
lesterol-lowering properties of PS esters of long-chain
unsaturated FA differ from that of long-chain saturated
FA.
In the current study, the PS-FO-fed group exhibited low-
ered fasting and postprandial triglyceride concentrations
beyond that observed with PS-SO and PS-OO. The hypot-
riglyceridemic effect of omega-3 FA consumption is well-
established [34]. Recently, we reported that PS-FO admin-
istration results in a greater reduction in triglyceride con-
centrations in comparison to FO consumption [19]. In
recent reports, vegetable oil FA esters of plant stanols were
shown to lower triglyceride concentrations in metabolic
syndrome subjects [35]. This effect was associated with
decreased very-low density lipoprotein production rates
and apolipoprotein CII and apolipoprotein CIII concen-
trations. These findings suggest that the obtained PS-FO
triglyceride-lowering effect may involve multiple mecha-
nisms of both free PS and omega-3 FA. Elucidating the
exact metabolic pathway by which PS-FO affect circulating
lipids warrants further study.
In addition to the reduction in the absorption of choles-
terol, daily consumption of PS esters for several weeks
effectively impedes the absorption in the gut of the
lipophilic carotenoids, such as β-carotene, lycopene and
α-tocopherol [10-12]. However, it was reported that the
consumption of a controlled diet [36], or increasing die-
tary carotenoid intake [37], may minimize this effect. In
our study, consumption of PS esters of vegetable oil as
part of an OO-based diet affected the plasma β-carotene
and retinol concentrations to a different degree as did PS
esters of omega-3 FA (PS-FO). Nonetheless, no differences
were detected between the PS-SO and PS-OO groups. Die-
tary β-carotene absorption in the intestine was shown to
be mediated via its solubilization in mixed micelles with
bile components, lecithin and hydrolyzates of dietary lip-
ids [38]. It was previously speculated that depletion of car-
otenoids from these micelles in the presence of PS was
dependent on the PS dosage, the background diet, and the
vehicle in which PS were solubilized [13]. When spreads
containing sitostanol esters of soybean, sheanut, or rice
Table 3: Endpoint serum fat-soluble vitamin concentrations (n = 21)
PS-SO2 PS-OO PS-FO P value3
Retinol (µg/dL) 65.0 ± 2.31, ab 64.7 ± 2.1a 70.2 ± 2.3b 0.0244
β-carotenes (µg/dL) 36.2 ± 3.4a 35.8 ± 3.3ab 42.0 ± 4.5b 0.0169
α-tocopherol (µg/dL) 1773 ± 138 1901 ± 117 1764 ± 142 0.2108
1Values are mean ± SEs.
2 PS-SO: plant sterols esterified with sunflower oil fatty acids; PS-OO: plant sterols esterified with olive oil fatty acids; PS-FO: plant sterols esterified 
with fish oil fatty acids
3 P values obtained by repeated-measures ANOVA.
a, b Values not sharing a common superscript letter are significantly different at P < 0.05.
Table 4: Endpoint plasma inflammation- and coagulation-related markers (n = 21)
PS-SO2 PS-OO PS-FO P value3
Inflammation
TNF-α (ng/L) 1.03 ± 0.191 1.03 ± 0.21 1.06 ± 0.24 0.9046
IL-6 (ng/L) 1.77 ± 0.22 1.91 ± 0.22 1.50 ± 0.17 0.1501
CRP (mg/L) 1.42 ± 0.48 1.48 ± 0.49 1.71 ± 0.63 0.8656
PSA4 (µg/L) 0.92 ± 0.10 0.84 ± 0.08 0.89 ± 0.09 0.6102
Coagulation
PAI-1 (µg/L) 40.3 ± 11.5a 26.6 ± 5.5ab 20.5 ± 2.6b 0.0297
Fibrinogen (g/L) 3.41 ± 0.15 3.42 ± 0.11 3.25 ± 0.11 0.2217
1 Values are means ± SE's.
2 CRP: C-reactive protein; IL-6: Interleukin-6; PAI-1: Plasminogen Activator Inhibitor 1; PSA: prostate specific antigen; PS-SO: plant sterols esterified 
with sunflower oil fatty acids; PS-OO: plant sterols esterified with olive oil fatty acids; PS-FO: plant sterols esterified with fish oil fatty acids; TNF-α: 
Tumor necrosis factor – α
3 P values obtained by repeated-measures ANOVA.
a, b Values not sharing a common superscript letter are significantly different at P < 0.05.
4 Chronic inflammation was suggested to play a role in the pathogenesis and progression of benign prostatic hyperplasia [54], which is associated 
with elevated PSA levels; n = 10Lipids in Health and Disease 2007, 6:28 http://www.lipidworld.com/content/6/1/28
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bran oil FA were compared, all reduced lipid-standardized
carotenoids albeit to a variable extent (9–43%) [39]. It has
been recently reported [12] that long-term consumption
of PS esters decreased plasma β-carotene concentrations
more than did free PS. In the PS-FO treatment the propor-
tion of PS-esters to free PS (~22%:5%) was somewhat
lower in compare to the PS-SO and PS-OO (~28%:1.5%)
supplements, but it is unlikely that the obtained results in
such a short intervention are associated with these differ-
ences. Furthermore, enhanced β-carotene bioavailability
and its conversion into vitamin A were reported in ani-
mals consuming micelles enriched with omega-9 and
omega-3 rather than omega-6 FA [40]. Our findings, as
well as those of others, suggest that solubilization of die-
tary carotenoids in mixed micelles is affected by the PS
vehicle, and that its characteristics contribute, at least in
part, to their bioavailability.
Several reports are favoring PS consumption for addi-
tional properties aside from their cholesterol-lowering
characteristics, including anti-oxidation, anti-inflamma-
tion, and anti-cancer [25,31,41,42] effects. The impact of
PS containing matrices on key risk factors for CHD, such
as CRP and other inflammation markers, is still controver-
sial [16,26,28-30]. Conversely, accumulated in vitro data
suggest that β-sitosterol may affect prostate cancer devel-
opment [43-46]. In our study, supplementation of PS
esters containing different FA did not affect plasma con-
centrations of inflammatory and coagulation markers, but
did alter PAI-1 levels. Previous observations showed that
consumption of PS esters [26,27] or FO [47] or both [48]
had no impact on the endothelial function marker PAI-1.
One possibility to explain this discrepancy might be the
presence of DAG in both PS-FO and PS-OO treatments
(1.4 g/d; 7:2 1,3:1,2-DAG) in the current study. Indeed, 3-
month DAG ingestion by Japanese patients with type 2
diabetes resulted in lowered PAI-1 concentrations com-
pared with the triacylglycerol oil group [49]. Though the
dosage of DAG in the present study was considerably
lower than in other clinical investigations [50], its con-
sumption might have contributed to the observed action
on PAI-1 concentrations.
Conclusion
Present data show that the effects of PS esters of omega-3
FA on circulating lipids, hydrocarbon carotenoids bioa-
vailability and PAI-1 concentrations differ from those of
PS-SO and PS-OO in mildly overweight, hypercholestero-
lemic subjects. These findings may suggest that the FA
moiety of PS esters and the other preparation compo-
nents, such as DAG, may provide an additional contribu-
tion to the overall beneficial impact. Therefore, in the
context of a Mediterranean-like diet, consumption of PS-
FO could exert in hyperlipidemic subjects a more compre-
hensive lipid lowering effect than vegetable oil esters of PS
while reducing the risk of decreases in plasma carotenoid
concentrations.
Methods
Subjects
The study protocol and the informed consent were
reviewed and approved by the Human Ethical Review
Committee of the Faculty of Agriculture and Environmen-
tal Sciences for the School of Dietetics and Human Nutri-
tion at McGill University (protocol number REB# 808-
0403). All subjects received explanations about the proto-
col and signed consent forms were obtained from each
participant.
Subjects were recruited by newspaper advertisement in
Montreal, Canada, and the surrounding areas. Potential
candidates were screened according to the following crite-
ria at Mary Emily Clinical Nutrition Research Unit of
McGill University. Inclusion criteria included men and
women, baseline LDL-cholesterol 2.6 mmol/l (100 mg/
dl), BMI ranging from 24 to30 kg/m2 and aged 30–65
years. Candidates were excluded from the study if they
had taken medications known to affect lipid metabolism,
such as cholestyramine, colestipol, gemfibrozil, probucol,
HMG-CoA reductase inhibitors; consumed FO capsules
and/or supplements containing PS during the previous 3
months; diagnosed with diabetes mellitus, kidney disease
or liver disease; were smokers; consumed more than two
glasses per day of alcoholic beverages; or took two or
more doses per week of laxatives or concentrated sources
of fibres.
Power calculation, based on a 0.56 mmol/l (standard
deviation of 0.84 mmol/l) change in the primary out-
come, LDL-cholesterol levels [51], at the 0.05 level of sig-
nificance and 80% power suggested that at least twenty
subjects would be required. Twenty-four volunteers,
eleven males, thirteen postmenopausal females, were
recruited according to the study protocol. Table 1 summa-
rizes the baseline characteristics of the twenty-one partici-
pants that completed the study.
PS preparations
The low-fat PS-SO margarine (Take control®) was kindly
donated by Unilever Bestfoods NA (Baltimore, MD). Both
the PS-OO and PS-FO oil supplements were manufac-
tured by Enzymotec LTD (Migdal HaEmeq, Israel). These
PS esters matrices were synthesized by a novel process in
which PS were esterified to OO- or FO-FA while produc-
ing DAG [52]. Table 5 lists the composition of the differ-
ent treatments. The FA composition of the PS-matrices
were identified according to American Oil Chemist' Soci-
ety official method and recommended practice Ce 1–62
(Champaign, IL). Briefly, the FA profiles were analyzed by
methanolysis of the FA in a sample of margarine or oilsLipids in Health and Disease 2007, 6:28 http://www.lipidworld.com/content/6/1/28
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extracted with a methanolic NaOH solution using BF3 as
catalyst. The methyl esters were extracted with n-heptane
and analyzed with a gas chromatograph (Agilent; Agilent
Technologies, Palo Alto, CA) equipped with CP-Sil 88 col-
umn (Supelco, Bellefonte, PA) and a flame ionization
detector on the basis of comparison of retention times
equal to those of authentic standards. All PS supplemen-
tations: 21.4 g low-fat PS-SO margarine, 9.1 g PS-OO oil,
and 9.6 g PS-FO oil provided an equivalent of 1.7 g soya-
bean sterols per day. PS-OO and PS-FO contained 1.4 g/d
DAG (7:2 of 1,3:1,2-DAG) as well, and PS-FO provided a
total of 1.7 g/d eicosapentaenoic acid and 3.7 g/d docosa-
hexaenoic acid. Tocopherol mixtures (0.2 % (w/w)) were
added to the base stock FO used as a source of FA for the
esterification of PS in the PS-FO preparation. No further
antioxidant beyond the original formulation was intro-
duced to the tested PS-FO or to other PS-matrices.
Experimental design
The study was a semi-randomized, crossover, double
blind clinical trial using a Latin square sequence. It con-
sisted of three phases of 28 d separated by a 4-week wash-
out interval. During each supplementation phase, the
subjects were provided by the clinic with an OO-based,
weight-maintaining, North-American diet, and through-
out the washout period, they consumed their own habit-
ual diets. This OO-based diet contained approximately
15% energy as protein, 55% energy as carbohydrates, 30%
energy as fat, of which approximately 70% was provided
by OO, 80 mg cholesterol per 1000 kcal, and 12 g fibre per
1000 kcal. Three isoenergetic meals (breakfast, lunch and
supper) were prepared according to a 3-d cycle menu in
the metabolic kitchen of the clinic, where the foods were
weighed precisely to 0.5 g during meal preparation. Sup-
plements were ingested at breakfast under supervision to
monitor compliance. The subjects were instructed to con-
sume only foods and beverages provided by the clinic,
and were encouraged to keep a constant exercise level
Table 5: Fatty acid and plant sterol composition of study formulations
PS-SO2 PS-OO PS-FO
Plant sterol esters (g/100 g of oil or margarine) 12.11 28.6 22.1
Free plant sterol equivalents (g/100 g of oil or margarine)
β-sitosterol 3.7 8.4 8.1
Campesterol 1.9 4.6 4.9
Stigmasterol 1.4 3.9 3.3
Brassicasterol 0.2 0.5 0.8
Others 0.5 1.0 1.1
Total 7.8 18.3 18.2
Fatty acids (% by weight of total fatty acids)
12:0 0.2 ND ND
14:0 0.2 ND 0. 5
16:0 8.3 12.8 1.1
16:1 0.1 0.9 0.7
17:0 0.1 ND 0.2
18:0 6.2 3.0 0.5
18:1 41.8 70.6 7.5
18:2 36.4 10.7 1.2
18:3 n-3 5.5 0.8 1.3
18:4 ND ND 4.0
20:0 0.5 0.5 0.1
20:1 0.3 0.2 3.1
20:4 n-6 ND ND 0.7
20:4 n-3 ND ND 2.6
20:5 n-3 ND ND 14.8
22:0 0.4 0.2 ND
22:1 ND ND 0.7
22:5 n-3 ND ND 4.6
22:6 n-3 ND ND 49.0
24:0 0.2 0.1 0.6
24:1 ND ND 0.2
Other fatty acids ND 0.1 0.6
1 Typical values; provided by Unilever and analyzed as previously described [39].
2 PS-SO: plant sterols esterified with sunflower oil fatty acids; PS-OO: plant sterols esterified with olive oil fatty acids; PS-FO: plant sterols 
esterified with fish oil fatty acids; ND, not detected.Lipids in Health and Disease 2007, 6:28 http://www.lipidworld.com/content/6/1/28
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throughout the study to ensure that bodyweights
remained unchanged.
Fasting blood samples were collected from the subjects on
days 1, 2, 28 and 29 of each phase. On the 28th day of each
phase, plasma postprandial triglyceride concentrations
were measured 4 h after breakfast.
Plasma lipid analysis
Serum total cholesterol, HDL-cholesterol, and triglyceride
concentrations were measured by automated methods on
the multianalyzer Dimension RxL Max utilizing enzy-
matic reagents Flex (Dade Behring Diagnostic, Marburg,
Germany). LDL-cholesterol concentrations were calcu-
lated using the Friedewald equation, unless the triglycer-
ide concentrations were > 4.5 mmol/l, in which case the
LDL- cholesterol concentrations were measured directly.
Plasma inflammation and coagulation markers
The serum TNF-α (Quantikine HS, R&D Systems Inc.,
Minneapolis, MN) and IL-6 (Quantikine HS, R&D Sys-
tems Inc.), and the plasma CRP (Roche Diagnostics Co.,
Indianapolis, IN), PSA (Abbott IMX, Montreal, Quebec,
Canada), and PAI-1 (PAI-1 Asserachrom, Diagnostica
Stago, Asnieres sur Seine, France) concentrations were
determined using the respective enzyme immunoassay
kits, according to the manufacturer's instructions. Fibrin-
ogen levels were measured on citrated plasma aliquot by
automated clot-rate assay based on the original method of
Clauss using the ACLAdvance instrument (Beckman
Coulter, Fullerton, CA).
Plasma fat-soluble vitamin concentrations
Plasma concentrations of the fat-soluble vitamins, retinol,
α-tocopherol, and β-carotene were measured by using
light-protected, reverse-phase HPLC as described else-
where [19,53]. Briefly, the fat-soluble components were
extracted from plasma using methanol and hexane (1:5
v:v) in the presence of internal standards (Sigma-Aldrich,
St Louis, MO); retinol acetate for retinol and tocopherol
acetate for α-tocopherol and β-carotene. The organic layer
was then transferred, dried, dissolved in methanol, and
injected into an HPLC column (JASCO, Dunmow, United
Kingdom) equipped with an ultraviolet detector and an
auto-injector system. The fat-soluble vitamins were iden-
tified and quantified using authentic standards (Sigma-
Aldrich), the corresponding standard curves, and multi-
wavelength detection.
Statistical analyses
All data were expressed as means and their standard errors
(SE). Statistical significance was set at α = 0.05 for all anal-
yses. Differences in plasma variables were tested by
repeated-measures ANOVA with the type of dietary matrix
in each intervention arm as the within-subject factor and
with endpoint values as the dependent variable. Baseline
values were inserted into the model as covariates if their
interaction with dietary matrices was found to be statisti-
cally significant. Subsequently, contrast analyses were
used to identify differences between pairs of diets. Fur-
thermore, a modified Cohen's effect size was calculated
for plasma lipid endpoint values to evaluate changes from
the baseline values. Data were analyzed using SAS soft-
ware (version 8.0; SAS Institute Inc, Cary, NC, USA).
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